Grants without peer review?

University College London is offering new unorthodox research grants for its staff without peer review, deadlines, directives, or milestones. The funding, which is open to any UCL employee, is in in the ballpark of £100,000 ($150,000) per year for at least three years for each awardee, according to UCL visiting earth sciences professor linkurl:Don Braben,;http://www.braben.com/VentureResearch/DB.html the scheme's brainchild and the founder of Venture Research International, a company that

Written byElie Dolgin
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
University College London is offering new unorthodox research grants for its staff without peer review, deadlines, directives, or milestones. The funding, which is open to any UCL employee, is in in the ballpark of £100,000 ($150,000) per year for at least three years for each awardee, according to UCL visiting earth sciences professor linkurl:Don Braben,;http://www.braben.com/VentureResearch/DB.html the scheme's brainchild and the founder of Venture Research International, a company that raises funds for blue skies research projects.
Unlike most lengthy grant proposals, initial applications are meant to be short -- less than 500 words long -- to detail only the research problem, its significance, and the resources needed. Successful first-round applicants will then sit down with Braben and UCL vice-provost for research linkurl:David Price,;http://www.es.ucl.ac.uk/people/price.htm who will make recommendations to UCL provost linkurl:Malcolm Grant,;http://www.ucl.ac.uk/provost/ who has the final say. The grants "will go to UCL researchers whose ideas challenge the norm and have the potential to change substantially the way we think about an important subject," UCL wrote on its linkurl:website.;http://www.ucl.ac.uk/research/venture-prize/ UCL launched the scheme -- called the Venture Research Prize -- as the antidote to the 2008 linkurl:Research Assessment Exercise;http://www.rae.ac.uk/ (RAE), the results of which will be published next Thursday (Dec. 18). The RAE, which evaluates the quality of research at British universities and is used to allocate national funds, has been criticized for narrowing research opportunities and only rewarding safe research. Peer review "automatically discriminates against ideas that challenge convention," Braben told __The Scientist__. "For most research, it's fine. But for new ideas that are a step out from what we understand -- and that's all the great ideas of the 20th century -- then peer review would work against them." In the 1980s, Braben's Venture Research initiative funded 26 research projects, all but one of which had been turned down by peer review. He points to successes, such as University of Liverpool chemist linkurl:Kenneth Seddon's;http://www.ch.qub.ac.uk/staff/seddon/krs.html discovery of ionic solvents, as evidence that the scheme works. Braben, who laid out some of his ideas in an linkurl:editorial;http://www.the-scientist.com/article/display/14971/ for __The Scientist__ in 2004, said that UCL has "set exceptionally high standards," and he dismissed the critique that he and Price will effectively serve as a peer-review panel of two. In the 1980s, he said, "we never had to have a debate as to whether someone was a venture researcher. It was obvious." UCL is looking for motivated researchers -- "from the humblest postdocs right on up" -- who "have a vision" and "want to substantially change the way we see the world," noted Braben. "What we really need is a Nobel Prize that people can apply for," he added. Funding people with this level of ambition will lead to valuable results, even if the original project proposal doesn't work out, Braben said. "You can't fail."
**__Related stories:__***linkurl:Peer review isn't perfect;http://www.the-scientist.com/article/display/55117/
[November 2008]*linkurl:Is peer review broken?;http://www.the-scientist.com/article/display/23061/
[February 2006]*linkurl:The wizard's warning;http://www.the-scientist.com/article/display/14971/
[27th September 2004]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies